Researchers at Oregon Health & Science University may have uncovered a new weapon for combating HIV as it is passed from mother to newborn child.
Harvard bioengineers have been awarded more than $3 million in funding from the National Institutes of Health and the U.S. Food and Drug Administration to develop a "Heart-Lung Micromachine" that will accelerate drug safety and efficacy testing.
CureVac GmbH announced first data from an open-label phase 1/2a clinical trial of its mRNA vaccine CV9103 in patients with hormone-refractory prostate cancer with rising PSA and existing metastasis in the vast majority of patients.
For hundreds of years, indigenous South Africans have chewed a plant they say reduces stress, relieves hunger, sedates and elevates moods. Now they have a license to study and market it, and plan to sell it over-the-counter worldwide.
It's a centerpiece of President Barack Obama's health care remake, a lifeline available right now to vulnerable people whose medical problems have made them uninsurable.
France's Sanofi-Aventis launched an $18.5 billion hostile takeover offer for Genzyme Corp., stepping up its effort to capture the U.S. biotech company's promising drugs for high cholesterol and lucrative treatments for rare genetic disorders.
Cerebral vasospasm is a common and potentially catastrophic delayed complication of subarachnoid hemorrhage (SAH). Subarachnoid hemorrhage is bleeding into the cerebral spinal fluid and usually is due to rupture of a brain aneurysm or to head trauma.
According to the latest statistics from the WHO, there are currently around 35 million people diagnosed with Alzheimer’s disease. Additionally, Parkinson’s disease, the most common motor disorder, affects about 0.1% to 0.2% of the western population.
TTP LabTech has announced a high throughput solution for chemotaxis research using the Acumen eX3 microplate cytometer and the iuvo Chemotaxis Assay Plate from BellBrook Labs.
Lonza now offers a broad selection of cryopreserved primary human diseased airway cells including, bronchial epithelial and smooth muscle cells, and lung fibroblasts from both chronic obstructive pulmonary disease, and asthmatic donors.
Cardialysis and Sticares InterACT announced that they have entered into a strategic collaboration to provide drug development consulting services in the field of cardiovascular and metabolic medicine.
AIKO Biotechnology announced the appointment of industry veteran Jim New, Ph.D., to the newly created position of chief executive officer.
Dyax Corp. and CMIC Co., Ltd, announced an agreement to develop and commercialize subcutaneous DX-88 (ecallantide) for the treatment of hereditary angioedema and other angioedema indications in Japan.
Avila Therapeutics, Inc. announced that it has initiated a phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of AVL-292, a novel, orally available, covalent drug that targets Bruton’s tyrosine kinase.